Anteris launches $250M at-the-market offering to fund DurAVR heart valve development

Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

• high

  Company established ability to sell up to $250 million of common stock through TD Securities at its discretion, potentially diluting existing shareholders over time as shares are sold into the market.

  Item 1.01 verify on EDGAR →
• high

  Proceeds will primarily fund ongoing development of DurAVR Transcatheter Heart Valve System, the company's core product, with remainder for working capital and general corporate purposes.

  Item 1.01 verify on EDGAR →
• medium

  TD Securities will receive 3% commission on gross proceeds from stock sales, with either party able to terminate the agreement upon ten days' notice.

  Item 1.01 verify on EDGAR →